Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT03741868
Official study title

Symptom Burden and Unmet Supportive Care Needs in Lung Cancer Patients Undergoing First or Second Line Immunotherapy

Study summary

Doctors are recruiting patients receiving care for lung cancer at the Wake Forest Baptist Comprehensive Cancer Center asking about needs and experiences during immunotherapy. Immunotherapy is a new treatment for lung cancer. The research is to better understand patients' perspectives on what immunotherapy is like and will provide important information to help understand the symptoms patients experience, the impact of treatment on daily life, ways that people adapt to the challenges of treatment, and services that may help people live better during treatment.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNot specified

The study team can explain what participation involves.

Who it may be forLung Neoplasm

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jul 24, 2020 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?2 U.S. locations

Locations may change over time.

Who runs it?Wake Forest University Health Sciences

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Wake Forest University Health Sciences
Interventions being studied
Not specified
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach
Immunotherapy→Supportive or behavioral care→
Study topics
After prior treatment→Survivorship and quality of life→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Histologically or cytologically confirmed stage IV (per AJCC 7th edition) non-small cell lung cancer.
  • Receiving first or second line immunotherapy.
  • ECOG Performance status of 0-3.
  • English-speaking
Reasons someone may not be able to joinExclusion criteria

Unable to provide informed consent

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Laurie E SteffenWinston-Salem, North Carolina
  • Wake Forest University Health SciencesWinston-Salem, North Carolina

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 24, 2020. Always confirm current availability with the study team.

View original record ↗